

IN THE CLAIMS:

Amend claim 18 as follows, the amendments being shown by brackets
and underlining in an Appendix hereto:

18. (Amended) A transdermal therapeutic system comprising a self-adhesive matrix layer containing the free base (-)-5,6,7,8-tetrahydro-6-[propyl-
1[2-(2-thienyl) ethyl]amino]-1-naphthalenol in an amount effective for the
treatment of the symptoms of Parkinson's syndrome, wherein the matrix is based
on a non-aqueous, acrylate-based or silicone-based polymer adhesive system
having a solubility of $\geq 5\%$ (w/w) for the free base (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl) ethyl]-amino]-1-naphthalenol; a backing layer inert to the
components of the matrix layer; and a protective foil or sheet covering the matrix
layer to be removed prior to use.

R E M A R K S

The 35 U.S.C. 112, first paragraph, rejection directed to the recitation
"substantially free..." has been obviated by the deletion of that recitation.